Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,835 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improving Diversity in a Novel Psoriasis Study: VISIBLE as a Framework for Clinical Trial Quality Improvement.
Alexis A, McMichael A, Vashi N, Bhutani T, Rodriguez AO, Yeung J, Choi O, Chan D, Alkousakis T, Bronner DN, Park-Wyllie L, Gao LL, Grimes P, Shahriari M, Yadav G, Kindred C, Taylor SC, Desai SR. Alexis A, et al. Among authors: chan d. JAMA Dermatol. 2024 Dec 11. doi: 10.1001/jamadermatol.2024.5103. Online ahead of print. JAMA Dermatol. 2024. PMID: 39661358
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study.
Ogdie A, Merola JF, Mease PJ, Ritchlin CT, Scher JU, Lafferty KP, Chan D, Chakravarty SD, Langholff W, Wang Y, Choi O, Krol Y, Gottlieb AB. Ogdie A, et al. Among authors: chan d. BMC Rheumatol. 2024 May 21;8(1):20. doi: 10.1186/s41927-024-00386-7. BMC Rheumatol. 2024. PMID: 38773563 Free PMC article.
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials.
Blauvelt A, Lebwohl M, Langley RG, Rowland K, Yang YW, Chan D, Miller M, You Y, Yu J, Thaҫi D, Foley P, Papp KA. Blauvelt A, et al. Among authors: chan d. J Am Acad Dermatol. 2023 Aug;89(2):274-282. doi: 10.1016/j.jaad.2023.03.035. Epub 2023 Apr 3. J Am Acad Dermatol. 2023. PMID: 37019386 Free article.
Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up.
Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, Hsu MC, You Y, Poulin Y, Korman N, Prinz JC, Reich K; PHOENIX 2 Investigators. Langley RG, et al. Among authors: chan d. Br J Dermatol. 2015;172(5):1371-83. doi: 10.1111/bjd.13469. Epub 2015 Mar 22. Br J Dermatol. 2015. PMID: 25307931 Free article. Clinical Trial.
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
Strober B, Coates LC, Lebwohl MG, Deodhar A, Leibowitz E, Rowland K, Kollmeier AP, Miller M, Wang Y, Li S, Chakravarty SD, Chan D, Shawi M, Yang YW, Thaҫi D, Rahman P. Strober B, et al. Among authors: chan d. Drug Saf. 2024 Jan;47(1):39-57. doi: 10.1007/s40264-023-01361-w. Epub 2023 Oct 31. Drug Saf. 2024. PMID: 37906417 Free PMC article. Clinical Trial.
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, Yeilding N, Li S, Szapary P, Gordon KB; PHOENIX 1 Investigators. Kimball AB, et al. Among authors: chan d. J Eur Acad Dermatol Venereol. 2013 Dec;27(12):1535-45. doi: 10.1111/jdv.12046. Epub 2012 Dec 20. J Eur Acad Dermatol Venereol. 2013. PMID: 23279003 Clinical Trial.
4,835 results